V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013830 | 160006753 | 1.82 | 94.1 | Curative (C) | 2018-12-26 | 2018-12-26 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101812785 |
| 160013831 | 160006754 | 1.68 | 97.4 | Palliative (P) | 2019-10-14 | 2019-10-23 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101402907 |
| 160013833 | 160006755 | 1.77 | 82.8 | Palliative (P) | 2018-09-13 | 2018-09-18 | Pemetrexed | 02 | N | NB RELAPSED CCLG GUIDELINES TVD | 100993106 |
| 160013835 | 160006756 | null | 79.7 | Curative (C) | 2019-06-24 | 2019-06-25 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100569017 |
| 160013837 | 160006757 | 1.5 | 86.3 | Palliative (P) | 2019-08-14 | 2019-09-12 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101070988 |
| 160013838 | 160006758 | 1.71 | 102.7 | null | 2018-05-19 | 2018-05-28 | VIDE | 02 | null | CISPLATIN + DOXORUBICIN | 101016284 |
| 160013839 | 160006759 | 1.89 | 86.4 | Palliative (P) | 2019-09-26 | 2019-10-17 | EW EuroEwing 2012 Arm A VIDE | 02 | N | DOXORUBICIN | 101226595 |
| 160013843 | 160006760 | 1.77 | 82 | Palliative (P) | 2017-01-31 | 2017-01-31 | Doxorubicin + Ifosfamide | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100302984 |
| 160013844 | 160006761 | 1.68 | 88.4 | null | null | 2018-04-24 | Liposomal Doxorubicin (20mg/m2) | null | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101273588 |
| 160013846 | 160006762 | 1.6 | 60 | Curative (C) | 2018-04-07 | 2018-04-15 | DOXORUBICIN | 01 | N | ETOP 13-18 BEAT-MESO TRIAL | 100761393 |
| 160013847 | 160006763 | 1.77 | 66.2 | Neo-adjuvant (N) | 2018-05-23 | 2018-05-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100955049 |
| 160013849 | 160006764 | 1.87 | 107.9 | null | 2017-06-17 | 2017-06-17 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101183019 |
| 160013851 | 160006765 | 1.46 | 86 | Neo-adjuvant (N) | 2016-07-11 | 2016-09-10 | STS Rhabdomyosarcoma RMS 2005 IVA | Y | null | LIPOSOMAL DOXORUBICIN | 100339549 |
| 160013855 | 160006766 | null | null | Palliative (P) | 2020-06-15 | 2020-06-15 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 101701712 |
| 160013857 | 160006767 | 1.82 | 78.25 | null | 2017-04-06 | 2017-04-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101059141 |
| 160013858 | 160006768 | 0 | 0 | Palliative (P) | 2016-03-23 | 2016-03-23 | Gemcitabine 1000mg/m2 D1 8 15 | null | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 100640624 |
| 160013859 | 160006769 | 1.55 | 75.4 | Neo-adjuvant (N) | 2019-08-07 | 2019-08-14 | CARBOPLATIN + PACLITAXEL | 2 | N | CARBOPLATIN + PACLITAXEL | 100379628 |
| 160013863 | 160006771 | 1.68 | 66 | 03 | 2016-12-22 | 2017-01-05 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101715121 |
| 160013864 | 160006772 | 0 | 2.9 | Neo-adjuvant (N) | 2019-06-08 | 2019-06-23 | Bevacizumab 7.5mg/kg | null | N | LIPOSOMAL DOXORUBICIN | 101544980 |
| 160013865 | 160006773 | 0 | 60.7 | Neo-adjuvant (N) | 2019-04-18 | 2019-05-02 | Cyclophosphamide + Vincristine | null | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100083813 |
| 160013867 | 160006774 | 1.89 | 115 | Palliative (P) | 2016-11-23 | 2016-11-24 | null | 02 | N | DOXORUBICIN + OLARATUMAB | 100240070 |
| 160013868 | 160006775 | 1.65 | 60.5 | Curative (C) | 2019-09-09 | 2019-09-28 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | TRIAL UNSPECIFIED | 100657525 |
| 160013869 | 160006776 | 1.74 | 85.6 | Palliative (P) | 2017-11-16 | 2017-11-16 | Oxaliplatin + Modified de Gramont | 2 | null | DOXORUBICIN + IFOSFAMIDE | 101288397 |
| 160013872 | 160006777 | 1.86 | 93.2 | Neo-adjuvant (N) | 2019-03-25 | 2019-04-02 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 101755754 |
| 160013881 | 160006778 | 1.68 | 88.2 | Palliative (P) | 2018-07-01 | 2018-07-03 | OST Euramos 1 Closed Trial - AP | N | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101649291 |
| 160013883 | 160006779 | 1.83 | 59.6 | Neo-adjuvant (N) | 2018-07-28 | 2018-09-16 | Trial Unspecified | 02 | N | EW EUROEWING 2012 ARM B VDC | 101776453 |
| 160013884 | 160006780 | 1.6 | 75.8 | Palliative (P) | 2016-08-05 | 2016-08-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101863464 |
| 160013885 | 160006781 | 1.79 | 73.55 | null | 2016-04-09 | 2016-04-17 | DOXORUBICIN | Y | null | DOXORUBICIN | 100288880 |
| 160013886 | 160006782 | 1.77 | 72.2 | Curative (C) | 2017-05-25 | 2017-05-25 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101216956 |
| 160013888 | 160006783 | 0 | 30 | Neo-adjuvant (N) | 2017-12-29 | 2017-12-29 | Carboplatin + Paclitaxel (3 weekly) | 2 | N | CARBOPLATIN + PACLITAXEL | 100465715 |
| 160013889 | 160006784 | 1.52 | 115 | Neo-adjuvant (N) | 2018-03-26 | 2018-03-27 | null | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100178106 |
| 160013890 | 160006785 | 1.62 | 83.65 | Palliative (P) | 2018-03-10 | 2018-03-18 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | CARBOPLATIN + PACLITAXEL | 100859511 |
| 160013892 | 160006786 | 1.57 | 115 | Palliative (P) | 2020-05-03 | 2020-05-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101088542 |
| 160013893 | 160006787 | 1.81 | 78.8 | Palliative (P) | 2019-10-21 | 2019-10-25 | Trial Unspecified | N | N | CARBOPLATIN | 101075858 |
| 160013895 | 160006788 | 1.54 | 72 | Neo-adjuvant (N) | 2015-09-15 | 2015-09-17 | Doxorubicin + Olaratumab | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101131185 |
| 160013898 | 160006789 | 1.74 | 85.1 | 03 | 2019-12-23 | 2020-01-05 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101756889 |
| 160013899 | 160006790 | 1.66 | 59.65 | null | 2018-02-19 | 2018-03-14 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100695352 |
| 160013903 | 160006791 | 1.64 | 50.8 | 03 | 2019-04-08 | 2019-04-15 | NB HRNBL-1 MOD N7 CAV | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100008631 |
| 160013904 | 160006792 | 1.61 | 73.8 | Palliative (P) | 2016-11-04 | 2016-11-04 | DOXORUBICIN | 02 | null | CISPLATIN + DOXORUBICIN | 101824226 |
| 160013909 | 160006793 | 0 | 79 | Palliative (P) | 2020-10-20 | 2020-10-21 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101301866 |
| 160013910 | 160006794 | 1.62 | 65 | Palliative (P) | 2016-03-24 | 2016-03-26 | ETOPOSIDE + RITUXIMAB | 02 | N | EURO-EWING | 101793356 |
| 160013911 | 160006795 | 1.68 | 69.7 | Palliative (P) | 2019-07-31 | 2019-08-02 | VINORELBINE | N | N | DOXORUBICIN + IFOSFAMIDE | 100143582 |
| 160013913 | 160006796 | 1.68 | 67.4 | Not known (9) | 2018-01-05 | 2018-01-25 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101348740 |
| 160013914 | 160006797 | 1.85 | 70.8 | Curative (C) | 2019-03-31 | 2019-04-21 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | PEMBROLIZUMAB | 100485889 |
| 160013915 | 160006798 | 1.8 | 68.1 | Palliative (P) | 2019-05-26 | 2019-06-13 | BEP 5 Day | 02 | N | NOT MATCHED | 100992974 |
| 160013916 | 160006799 | 1.78 | 78.6 | Curative (C) | 2016-06-01 | 2016-06-05 | Liposomal Doxorubicin (Caelyx) | 02 | N | NIVOLUMAB | 101553787 |
| 160013917 | 160006800 | 1.46 | null | Palliative (P) | 2017-12-03 | 2017-12-23 | GEMCARBO | 02 | N | TRIAL UNSPECIFIED | 100696840 |
| 160013918 | 160006801 | null | 71.9 | Palliative (P) | 2017-10-17 | 2017-10-17 | STS Rhabdo RMS 2005 | 02 | null | STS RHABDO RMS 2005 | 100311164 |
| 160013919 | 160006802 | 1.5 | 90 | Palliative (P) | 2017-10-26 | 2017-12-07 | null | N | N | PACLITAXEL | 101647408 |
| 160013920 | 160006803 | 1.7 | 60 | null | 2016-07-26 | 2016-08-09 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100933613 |